AUS
NZ
UK
CA
USA
IND
Highlights
- Private equity bidder Cosette exits deal citing earnings and regulatory issues
- Mayne Pharma's (MYX) stock tumbles 30% amid legal tussle
- Market volatility, earnings downgrade, and FDA scrutiny shake confidence
In a dramatic turn of events that highlights how fragile M&A transactions can become in uncertain times, Cosette Pharmaceuticals has decided to pull back from its proposed $672 million acquisition of Mayne Pharma (ASX:MYX), a deal originally announced with optimism in February.
The two parties began confidential discussions back in September 2024, a period marked by more stable economic conditions. However, market dynamics have shifted significantly since then. Rising global volatility, tightening economic outlooks, and unexpected regulatory scrutiny appear to have triggered serious concerns for Cosette.
At the center of the dispute is Mayne Pharma’s recent financial performance. In February, Mayne reported first-half underlying EBITDA of $31 million and expressed confidence in achieving growth in the second half of FY2025. This implied full-year earnings in the ballpark of $62 million, far exceeding analyst expectations at the time.
However, in April, the company revised its guidance downward to $47–$51 million EBITDA. While still an improvement year-on-year, the downgrade was notable — especially considering Cosette had just signed the deal days earlier.
To complicate matters further, Mayne’s flagship contraceptive pill, Nextstellis, came under scrutiny from the US Food and Drug Administration (FDA). The regulator accused the company of downplaying risks in its promotional material. While Mayne claims to have disclosed this information to Cosette, it chose not to inform shareholders — a move raising questions about transparency.
Cosette now argues that the combination of revised earnings and regulatory concerns constitutes a “material adverse change,” a clause in the 111-page scheme document that, if triggered, allows a bidder to renegotiate or walk away. Mayne, however, disputes this interpretation, and the situation has escalated into a rare legal confrontation over the deal's future.
This breakdown is an outlier, especially within the normally orderly realm of S&P/ASX200 mergers. For context, such disputes around material adverse change clauses are rare in transactions involving major listed entities like those on the ASX200 stocks.
Market watchers suggest broader uncertainty and risk aversion are influencing corporate behavior. With deal confidence shaken, even strong contenders are hesitating. The landscape is starkly different from the more bullish sentiment seen in past quarters.
As investors increasingly seek stability amid such volatility, many are turning their attention to more consistent performers like ASX dividend stocks, which are often favored during unpredictable cycles.
For Mayne and Cosette, the road ahead now runs through legal teams and negotiated settlements, offering a front-row seat to one of the more contentious M&A sagas in recent ASX200 history.
